期刊
CHEMICAL SOCIETY REVIEWS
卷 45, 期 1, 页码 152-168出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c5cs00674k
关键词
-
资金
- FAPESP [2012/17053-7]
- Deutsche Forschungsgemeinschaft (DFG)/German Research Foundation [SFB1112]
- Bundesministerium fur Bildung und Forschung (BMBF) through the NanoMatFutur award [13N12561]
- Helmholtz Virtual Institute, Multifunctional Biomaterials for Medicine
- Freie Universitat Berlin Focus Area Nanoscale
- Brazilian Network on Nanotoxicology (MCTI/CNPq)
Leishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa, threatens 350 million people in 98 countries around the world. There are already 12 million infected people worldwide and two million new cases occur annually. Leishmaniasis has three main clinical presentations: cutaneous (CL), mucosal (ML), and visceral (VL). It is considered an opportunistic, infectious disease and the HIV-leishmaniasis correlation is well known. Antimonial compounds are used as first-line treatment drugs, but their toxicity, which can be extremely high, leads to a number of undesirable side effects and resultant failure of the patients to adhere to treatment. There is also a reported increase in Leishmania sp. resistance to these drugs. Nanotechnology has emerged as an attractive alternative because of its improved bioavailability and lower toxicity, and other characteristics that help to relieve the burden of this disease. In this review we will present some of the recent advances in the nanotechnological research regarding the treatment of leishmaniasis. The preclinical results regarding the approaches for a biomedical treatment of the disease have been encouraging, but further efforts will still be necessary for this therapy to have greater clinical applicability in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据